Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.

J Biomol Struct Dyn

a Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy , Tianjin Medical University, Tianjin , China.

Published: November 2018

Noonan syndrome (NS) is a common autosomal dominant congenital disorder which could cause the congenital cardiopathy and cancer predisposition. Previous studies reported that the knock-in mouse models of the mutant D61G of SHP2 exhibited the major features of NS, which demonstrated that the mutation D61G of SHP2 could cause NS. To explore the effect of D61G mutation on SHP2 and explain the high activity of the mutant, molecular dynamic simulations were performed on wild type (WT) of SHP2 and the mutated SHP2-D61G, respectively. The principal component analysis and dynamic cross-correlation mapping, associated with secondary structure, showed that the D61G mutation affected the motions of two regions (residues Asn 58-Thr 59 and Val 460-His 462) in SHP2 from β to turn. Moreover, the residue interaction networks analysis, the hydrogen bond occupancy analysis and the binding free energies were calculated to gain detailed insight into the influence of the mutant D61G on the two regions, revealing that the major differences between SHP2-WT and SHP2-D61G were the different interactions between Gly 61 and Gly 462, Gly 61 and Ala 461, Gln 506 and Ile 463, Gly 61 and Asn 58, Ile 463 and Thr 466, Gly 462 and Cys 459. Consequently, our findings here may provide knowledge to understand the increased activity of SHP2 caused by the mutant D61G.

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.2017.1402709DOI Listing

Publication Analysis

Top Keywords

d61g mutation
12
mutant d61g
12
mutation shp2
8
d61g shp2
8
gly 462
8
ile 463
8
shp2
7
d61g
6
gly
5
exploring d61g
4

Similar Publications

Background: RASopathies are genetic syndromes affecting development and having variable cancer predisposition. These disorders are clinically related and are caused by germline mutations affecting key players and regulators of the RAS-MAPK signaling pathway generally leading to an upregulated ERK activity. Gain-of-function (GOF) mutations in PTPN11, encoding SHP2, a cytosolic protein tyrosine phosphatase positively controlling RAS function, underlie approximately 50% of Noonan syndromes (NS), the most common RASopathy.

View Article and Find Full Text PDF

Background: We have previously shown that SHP2 downregulation may predispose fibroblasts to differentiate into myofibroblasts and proposed a role for SHP2 downregulation in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Recent data have shown that SHP2 localizes to the mitochondrial intercristae, and its overexpression enhances mitochondrial metabolism leading to oxidative stress and senescence.

Objective: To determine the effect of SHP2 on fibrotic responses.

View Article and Find Full Text PDF

Objective: To explore the synergistic effect and metabolic mechanism of chronic arsenic exposure and gain-of-function mutation on tumorigenesis.

Methods: Arsenic-transformed (WT-As) and -mutant (D61G-As) mouse embryonic fibroblasts (MEFs) were established by chronic treatment of low-dose arsenic. We used cell counting, plate colony and soft agar colony formation, and a nude mouse xenograft model to detect malignant transformation and tumorigenesis and .

View Article and Find Full Text PDF
Article Synopsis
  • Gain-of-function mutations in SHP2 are commonly found in sporadic juvenile myelomonocytic leukemia (JMML) and myeloproliferative neoplasms (MPN) associated with Noonan syndrome (NS).
  • Researchers studied the gene expression of hematopoietic stem and progenitor cells (HSPCs) with SHP2 mutations from JMML patients and a new zebrafish model, finding an inflammatory gene pattern.
  • Treatment with an anti-inflammatory agent improved the JMML-like MPN in zebrafish embryos, suggesting inflammation in HSPCs might be a potential therapeutic target for JMML.
View Article and Find Full Text PDF

We developed a new class of inhibitors of protein-protein interactions of the SHP2 phosphatase, which is pivotal in cell signaling and represents a central target in the therapy of cancer and rare diseases. Currently available SHP2 inhibitors target the catalytic site or an allosteric pocket but lack specificity or are ineffective for disease-associated SHP2 mutants. Considering that pathogenic lesions cause signaling hyperactivation due to increased levels of SHP2 association with cognate proteins, we developed peptide-based molecules with nanomolar affinity for the N-terminal Src homology domain of SHP2, good selectivity, stability to degradation, and an affinity for pathogenic variants of SHP2 that is 2-20 times higher than for the wild-type protein.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!